Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Yasuhiko Iwamoto 1) , Tadaaki Taniguchi 2) , Kenji Nonaka 2) , Taro Okamoto 2) , Kotoba Okuyama 2) , Juan Camilo Arjona Ferreira 3) and John Amatruda 3) GIP in vivo are short-lived due to their rapid degradation and inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4) [3, 4] . Sitagliptin is an oral, potent, highly selective, oncedaily DPP-4 inhibitor indicated for the treatment of type 2 diabetes mellitus (T2DM) [5] . Sitagliptin increases plasma levels of intact GLP-1 and GIP by twoto three-fold in patients with T2DM and in healthy volunteers [6] [7] [8] [9] . In previously published studies conducted in non-Japanese patients with T2DM, treatment with sitagliptin was shown to reduce glycosylated he-(Banyu Pharmaceutical Co., LTD. Protocol Number A202/Merck & Co., inc. Protocol Number 044) was reviewed and approved by the appropriate committees and authorities at each study site and conducted in accordance with the Declaration of Helsinki. This study was performed between the dates of July 11, 2005 and March 8, 2006 .
Study Design
This Phase II, randomized, double-blind, placebocontrolled, parallel-arm study (www.clinicaltrials.gov registry number: NCT00127192) was conducted at 97 sites in Japan. At screening/Visit 1, the HbA 1c inclusion criteria ranged from ≥6.5% to <10% for patients not on an OHA (for at least 8 weeks) and ≥6% to ≤9% for patients on OHA monotherapy (within 8 weeks prior to Visit 1). The study included a screening diet/ exercise run-in period of up to 8 weeks, including a 2-week single-blind placebo run-in period. At Visit 2, patients who had been on a diet and exercise program for at least 6 weeks and who had not taken an OHA for at least 6 weeks were eligible to directly enter the placebo run-in period. All other patients underwent a 6-week diet and exercise program (and wash-off period for patients on OHA at screening) prior to entering the placebo run-in period. This design ensured that patients received ≥8 weeks of diet and exercise therapy without OHA treatment before randomization.
Patients with an HbA 1c ≥6.5 and <10% and a fasting plasma glucose (FPG) ≤270 mg/dL upon entering the placebo run-in period and with ≥75% compliance with the single-blind placebo were randomized (1:1:1:1:1) to double-blind treatment with placebo or with sitagliptin 25 mg, 50 mg, 100 mg, or 200 mg administered once daily before breakfast for 12 weeks. Patients were allocated to treatment assignment using an allocation schedule created by a Japanese thirdparty vendor that packaged the clinical supplies and provided them to the clinical site. Numbered containers were used to implement allocation and each patient was assigned the next number in the sequence upon being enrolled. All study personnel, including investigators, study site personnel, patients, monitors, and central laboratory personnel, remained blinded to treatment allocation throughout the study; the code was revealed to the researchers only after case report forms were completed, the database was locked, and statistical analysis plans were finalized. During the double-blind active treatment phase, patients received moglobin (HbA 1c ) as well as fasting and postprandial glucose levels in a dose-dependent manner [10, 11] . Sitagliptin is administered once daily as a single 100-mg tablet in non-Japanese patients with normal to mildly impaired renal function, [12] as this dosing regimen was considered optimally effective in large multinational clinical dose-range finding studies [10, 11, 13, 14] . Because sitagliptin is primarily renally excreted, sitagliptin dose adjustments to achieve plasma concentrations comparable to those in patients with normal renal function are recommended for patients with T2DM who have moderate renal insufficiency or severe renal insufficiency, including those with endstage renal disease requiring dialysis [12, 15, 16] .
In a recently published study, treatment with sitagliptin 100 mg q.d. for 12 weeks improved fasting and postprandial glycemic control and was generally well-tolerated in Japanese patients with T2DM [17] . We have previously reported that sitagliptin possesses similar pharmacokinetic and pharmacodynamic profiles in healthy Japanese and non-Japanese subjects [7, 8, 17] . The aim of the current study was to evaluate the glycemic efficacy, dose response, and safety/tolerability profile of sitagliptin 25, 50, 100, and 200 mg administered once daily for 12 weeks in a population of Japanese patients with T2DM.
Patients and methods

Patients
Male and female Japanese patients aged 20 to 75 years with T2DM were eligible to participate if they had inadequate glycemic control and, at screening, were either taking an oral anti-hyperglycemic agent (OHA) or had not taken an OHA for at least 8 weeks. Patients with type 1 diabetes, history of diabetic ketoacidosis, serum C-peptide ≤0.7 ng/dL at screening, treatment with insulin, PPARγ agonist (pioglitazone) or any combination OHA therapy in the 8 weeks prior to screening, unstable cardiac disease, active liver or gallbladder disease, inadequately controlled hypertension (systolic or diastolic blood pressure >160 mm Hg or >100 mm Hg, respectively), elevated serum creatinine (>1.3 mg/dL in men and >1.2 mg/dL in women), and elevations >2-fold the upper limit of normal (ULN) in alanine aminotransferase (ALT) and/ or aspartate aminotransferase (AST) were excluded. All patients provided written informed consent prior to the conduct of study procedures. The protocol was not required to assess an episode as hypoglycemia, although investigators could include the fingerstick glucose measurement, if it was available, in their assessment of the episode.
All efficacy and safety laboratory measurements were assayed at a central laboratory (Mitsubishi Kagaku Bio-Clinical Laboratories [Mitsubishi Chemical Medience Corporation], Tokyo) by technicians blinded to treatment allocation.
Statistical Analyses
efficacy analyses were performed on the full analysis set (FAS) consisting of all randomized patients who received at least one dose of study drug and who had valid measurements both at baseline and at least one post-treatment measurement. The primary efficacy endpoint, the change from baseline in HbA 1c at Week 12, was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, prior OHA use, and baseline HbA 1c value as covariates. The between-group differences (relative to placebo) and associated 95% confidence intervals (Cis) for efficacy endpoints were assessed by testing the differences in the least squares (LS) mean changes from baseline at Week 12. Missing data were handled using the last observation carried forward method. An alpha level of <0.050 (two sided) was considered statistically significant. A stepwise linear contrast test based on the ANCOVA model was used to examine the dose-response relationship for placebo and the sitagliptin 25-, 50-, 100-, and 200-mg groups. LS mean differences between groups (relative to placebo) and associated 95% CI for each of the subgroups were estimated based on the aforementioned ANCOVA model to evaluate the consistency of the HbA 1c -lowering effect of sitagliptin relative to placebo across predefined subgroups including baseline HbA 1c stratum (≤8.0% or >8.0%).
Safety analyses were performed on the all-patients-as-treated population (APaT) consisting of all patients who took at least one dose of study drug. Summary statistics for changes from baseline in safety continuous parameters were calculated. For overall AEs, drug-related AEs, hypoglycemia, and selected gastrointestinal-related AEs (i.e., nausea, vomiting, and diarrhea), the comparisons with placebo were conducted by Fisher's exact test, and between-group differences (relative to placebo) and associated 95% CIs were reported. diet and exercise therapy. A follow-up phone call was made 14 days after the final dose of study medication to query patients regarding potential adverse experiences (AEs).
Endpoints
After an overnight fast, blood was collected for the assessment of HbA 1c , FPG, 1,5-anhydroglucitol (1,5-AG), and glycosylated albumin (GA) at baseline (i.e., Week 0 prior to the first dose of study medication) and at various time points throughout the study. Homeostasis model assessment-β cell (HOMA-β) was calculated to estimate pancreatic β-cell function. All patients were administered a standard meal tolerance test (MTT) at baseline and at Week 12. Patients took study medication 30 minutes prior to the standard meal, which was ingested within 15 minutes and contained 500 kcal: 60% from carbohydrate, 15% from protein, and 25% from fat. Plasma glucose, insulin, and C-peptide concentrations were measured at 0, 30, 60, and 120 minutes from the start of the meal for determination of 2-hour PPG, area under the glucose concentration-time curve (AUC), insulin AUC, and C-peptide AUC. The insulinogenic index was measured by calculating the ratio of the change in postprandial insulin/glucose from baseline to 30 minutes [17] . Plasma glucagon levels were measured at 0, 30, 60, and 120 minutes during the MTT in a subset of patients enrolled at clinic sites that were equipped to adequately collect and process the samples.
Safety and tolerability were evaluated from AE reports, vital signs (blood pressure, pulse rate and body weight), 12-lead electrocardiograms (ECGs), and laboratory tests, including hematology, blood chemistry, and urinalysis. AEs were rated by the investigators for the intensity and the potential relationship (definitely not, probably not, possibly, probably, or definitely) to study drug. AEs of special interest included hypoglycemia and selected gastrointestinal-related AEs (i.e., nausea, vomiting, and diarrhea). Patients were counseled to record results of self-monitored blood glucose levels and symptoms of hypoglycemia (e.g., sweating, anxiety, palpitations, headache, blurred vision, clouding of consciousness in diaries) for proper assessment of hypoglycemic events during the study. Hypoglycemia was assessed by the study site investigators through reviewing patient self-reports of signs and symptoms of hypoglycemia. A fingerstick blood glucose determination concurrent with the episode tients discontinued before study completion. The discontinuation rate was somewhat higher in the placebo group relative to the sitagliptin groups, with withdrawal of consent and lack of efficacy being the most common reasons for discontinuation. All randomized patients contributed to the efficacy and safety analyses. Baseline demographics were generally well matched, and baseline glycemic characteristics were similar across the treatment groups (Table 1) . Patients randomized in this study had a mean baseline HbA 1c of 7.60% and FPG of 147.5 mg/dL. The mean duration of diabetes was 5.4 years, and 51.5% of pa-
results
Of 473 patients screened for participation in this study, 110 were not randomized because they did not meet inclusion or met exclusion criteria (n=85), withdrew consent (n=20), or other reason (n=5). A total of 363 patients were randomized to receive doubleblind treatment with once-daily placebo (n=73), sitagliptin 25 mg (n=80), 50 mg (n=72), 100 mg (n=70), or 200 mg (n=68) for 12 weeks (Figure 1 ). Overall, 351 (97%) patients completed the study, and 12 pa- Figure 3 ). The reductions observed at doses of 100 and 200 mg were numerically but not statistically superior to 50 mg. The only pairwise comparison that reached statistical significance was between the 25-mg and 200-mg groups (p<0.050). Compared with placebo, sitagliptin also led to significant (p<0.001 for all doses of sitagliptin) dose-related increases from baseline in 1,5-AG and significant (p<0.001 for all doses of sitagliptin) dose-related reductions from baseline in GA (Table 2) .
Relative to placebo, all doses of sitagliptin produced significant dose-related increases from baseline in HOMA-β (p<0.050 vs. placebo for all doses) ( Table 2 ). There were no significant differences in the HOMA-β response among the 25-, 50-, 100-, and 200-mg doses, except for a significant difference observed when the 25-mg group was compared with the 100-mg group (p=0.030).
With respect to the MTT parameters, treatment with sitagliptin across all doses tested led to significant reductions from baseline in 2-hr PPG and glucose AUC 0-2 hr relative to placebo at Week 12 (p<0.001 vs. placebo for all doses), with the 200-mg group providing the largest magnitude changes from baseline in both parameters (Table 2) . No significant betweengroup differences in 2-hr PPG were seen between the sitagliptin 25-and 50-mg doses or among sitagliptin doses of 50, 100, and 200 mg. In contrast, the 25-mg dose produced significantly smaller reductions in 2-hr PPG compared with the 100-mg (p=0.010) and 200-mg doses (p<0.001) (data not shown). No significant between-group differences in glucose prior to AUC 0-2 hr were seen between sitagliptin doses of 50 and 100 mg or between sitagliptin doses of 100 and 200 mg; however, significantly smaller reductions in glucose AUC 0-2 hr were observed with sitagliptin 25 mg compared with sitagliptin 50 mg, 100 mg, and 200 mg (p=0.026, p=0.004 and p<0.001, respectients had received prior OHA therapy within 8 weeks before initiation of the screening period.
Efficacy
At Week 12, all doses of sitagliptin produced significant reductions from baseline in HbA 1c (p<0.001) ( Table 2) 
Safety
Compared with the placebo group, the incidences of overall clinical AEs were similar in the 25-mg group, with a dose-related trend toward an increased incidence across the 50-, 100-, and 200-mg groups (Table 3 ). There were similar proportions of patients across the placebo, sitagliptin 25-, 50-, 100-, and 200-mg groups for whom infections and infestations dis- [17.6%] for the placebo, sitagliptin 25-, 50-, 100-, and 200-mg groups, respectively). The incidences of hypoglycemia and selected gastrointestinal AEs across the sitagliptin groups were low and comparable to that seen in the placebo group (Table 3) . Only one patient in this study (a patient in the 200-mg group) discontinued due to a clinical AE; a clinical AE of myocardial ischemia determined by the investigator to be "definitely not related" to study medication.
The incidences of drug-related clinical AEs were generally similar between the placebo and the individual sitagliptin groups, with no apparent dose-related trend (Table 3 ). There were no clinically meaningful differences in the incidences of specific drug-related clinical AEs across the groups (Table 3) . No patients in this study discontinued due to drug-related clinical AEs (Table 3 ). There were 3 patients for whom 5 serious AEs were reported.
All serious AEs were determined by the investigator to be "definitely not related" to study medication: 1 patient in the 50-mg group (angina pectoris) and 2 patients in the 200-mg group (one patient had an overdose and 1 patient reported AEs of cardiac failure, hypertensive heart disease, and myocardial ischemia). Per protocol, overdose was defined as a serious AE, regardless of whether an adverse event was associated with the overdose. The patient for whom an AE of overdose was reported took sitagliptin 400 mg/day for one day without any associated adverse signs or symptoms. No patients discontinued due to serious clinical AEs. tively) and with 50 mg compared with 200 mg (p=0.049) (data not shown). Of all the sitagliptin doses tested, only the 200-mg group produced significant increases from baseline in insulin AUC 0-2 hr (p=0.030) and C-peptide AUC 0-2 hr (p<0.001) compared with placebo. The insulinogenic index was significantly increased with sitagliptin 100 and 200 mg compared with placebo (p<0.050). The effects of sitagliptin on plasma glucagon levels were examined in a subset of patients enrolled at sites equipped to appropriately collect and process the samples. Although the predefined stepwise linear contrast test that included the 200-mg dose was not significant, treatment with sitagliptin 25, 50 and 100 mg led to significant (p<0.001 in 50 mg, p<0.05 in 25 and 100 mg) reductions from baseline in glucagon AUC 0-2 hr Significant reductions from baseline relative to placebo were observed for the 50-and 100-mg doses of sitagliptin (p<0.05). tin 50 mg, 100 mg, and 200 mg, respectively). Two (2.5%), 3 (4.3%), and 3 (4.4%) of patients in the sitagliptin 25-, 100-, and 200-mg groups were reported to have an AE of proteinuria compared with none in the placebo and sitagliptin 50-mg groups. There was no evidence of a dose-related trend toward increased incidences of laboratory AEs across the sitagliptin groups. There was no dose-dependent increase in the proportion of patients in these groups for whom laboratory AEs were reported (8 (11.0%), 15 (18.8%), 14 (19.4%), 12 (17.1%), and 8 (11.8%) in the placebo, sitagliptin 25-, 50-, 100-, and 200-mg groups, respectively (Table 3) , with similar incidences observed for the placebo and 200-mg groups. Among the specific laboratory Aes, a total of 4 patients in the 50-mg group experienced elevations in ALT (4 [5.6%]) and AST (3 [4.2%]) versus none in the higher-dose groups. There was a higher incidence of creatine kinase elevations in the 25-mg group (7 [ PPG, glucose AUC 0-2hr, 1,5-AG, and GA. For FPG, 2-hr PPG, and glucose AUC 0-2hr ; stepwise numerically greater improvements were observed across the entire dose range, suggesting that some patients in this population may receive additional benefit from a higher dose of sitagliptin. The 50-mg dose produced significantly greater improvements in 1,5-AG and GA relative to the 25-mg dose, with no further improvements observed at doses of 100 and 200 mg. The combined improvements in FPG, 2-hr PPG and glucose AUC 0-2hr observed in this study of Japanese patients demonstrates that sitagliptin provides clinically meaningful glucose-lowering efficacy in both the fasting and postprandial states. All sitagliptin doses provided numerical increases relative to placebo in insulin AUC 0-2hr , although statistical significance was reached at the 200-mg dose only. The effects of sitagliptin therapy on plasma insulin levels in the context of lowered glucose excursion suggest that sitagliptin may enhance the insulin response following a meal. Significant improvements in β-cell function were observed with all sitagliptin doses relative to placebo using both fasting and postprandial measurements (i.e., HOMA-β and insulinogenic index). This study also assessed the effects of sitagliptin on plasma glucagon levels in a subset of patients enrolled at clinic sites equipped to adequately collect and process the samples for this assay. Treatment with sitagliptin 25, 50, or 100 mg led to significant reductions from baseline in glucagon AUC 0-2hr , although there was no evidence of a doserelated trend in the glucagon response. Significant reductions from baseline in glucagon AUC 0-2hr were also observed with sitagliptin 50 and 100 mg relative to placebo. Consistent with the glucagon-lowering previously reported by Herman et al. [5] , this finding suggests that sitagliptin alters the secretion of glucagon by the α-cell, although further research may better elucidate the effects of sitagliptin on hepatic glucose output. Consistent with prior findings in non-Japanese patients, there was no significant effect of sitagliptin treatment compared with placebo on HOMA-iR in the current study (data not shown), suggesting that sitagliptin does not affect peripheral insulin sensitivity [10, 11, 13, 14] .
In this study, there were numerical incremental improvements in both FPG and 2-hr PPG with sitagliptin doses of 100 (N=70) and 200 mg (N=68) relative to the 50-mg dose (N=72); however, the differences obprematurely due to laboratory AEs.
At Week 12, treatment with sitagliptin had no clinically meaningful effect on body weight relative to baseline or placebo. The placebo group showed a small non-significant reduction from baseline in body weight of -0.5 kg (95% Ci: -0. 
Discussion
This 12-week, placebo-controlled, randomized study evaluated the glycemic efficacy, dose-response and safety/tolerability profile of sitagliptin doses ranging from 25 to 200 mg q.d. in Japanese patients with T2DM who had inadequate glycemic control with diet and exercise therapy alone. Treatment with sitagliptin monotherapy led to significant dose-related and clinically meaningful reductions in HbA 1c relative to placebo after 12 weeks of treatment. The 50-mg dose of sitagliptin was maximally effective at reducing HbA 1c , with similar magnitude reductions observed in the 100-mg group and only small numerically greater reductions in the 200-mg group. This finding suggests that, in Japanese patients with T2DM, starting treatment with the 100-and 200-mg doses of sitagliptin does not provide further, clinically meaningful improvements in HbA 1c beyond that seen with the 50-mg dose in this treatment period. The improvements in HbA 1c observed in this study of Japanese patients with T2DM were maintained over the 12-week treatment period for all sitagliptin doses, whereas deterioration was observed in the placebo group. A previous, longer-term study conducted in non-Japanese patients with T2DM demonstrated that sitagliptin doses of 100 and 200 mg produced maximum reductions in HbA 1c by Week 12 with no further improvements observed out to week 18 [14] .
In addition to reductions in HbA 1c , treatment with sitagliptin also provided significant dose-dependent improvements in other important glycemic endpoints compared with placebo, including FPG, 2-hr placebo group. This finding is consistent with evidence indicating that GLP-1 stimulates insulin release in a glucose-dependent manner [18] . The incidence of gastrointestinal AEs was evaluated in this study since sitagliptin increases the level of active GLP-1 in the plasma and GLP-1 analogues are known to be associated with symptoms of nausea, vomiting, and diarrhea [19] . In this study, the incidence of gastrointestinal AEs was very low with no clinically meaningful differences between the sitagliptin and placebo groups. Finally, treatment with sitagliptin had a generally neutral effect on body weight without evidence of a doserelated increase. In conclusion, this 12-week study in Japanese patients with T2DM and inadequate glycemic control on diet and exercise therapy alone demonstrated that once-daily sitagliptin at doses of 25, 50, 100, and 200 mg provided statistically significant and clinically important reductions in HbA 1c , FPG, and 2-hr PPG as well as significant improvements in indices of insulin secretion and β-cell function, including HOMA-β and insulinogenic index. Treatment with sitagliptin was well tolerated and was associated with a low rate of hypoglycemia as well as a neutral effect on body weight.
